<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206370</article-id><article-id pub-id-type="doi">10.1101/2025.06.08.658472</article-id><article-id pub-id-type="archive">PPR1033126</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Proteomic analysis of bronchoalveolar lavage fluid after lung transplantation associates stable allograft function with less lung damage at 12 months</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Arike</surname><given-names>Liisa</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Johansson</surname><given-names>Kristina</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ermund</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Greer</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pelaseyed</surname><given-names>Thaher</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Westin</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hansson</surname><given-names>Gunnar C</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5630-0155</contrib-id><name><surname>Magnusson</surname><given-names>Jesper M</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="corresp" rid="CR1">⁋</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tm6cn81</institution-id><institution>University of Gothenburg</institution></institution-wrap>, <city>Gothenburg</city>, <country country="SE">Sweden</country></aff><aff id="A2"><label>2</label>Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tm6cn81</institution-id><institution>University of Gothenburg</institution></institution-wrap>, <city>Gothenburg</city>, <country country="SE">Sweden</country></aff><aff id="A3"><label>3</label>Department of Respiratory Medicine &amp; Infectious Diseases, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f2yqf98</institution-id><institution>Hannover Medical School</institution></institution-wrap>, <city>Hannover</city>, <country country="DE">Germany</country></aff><aff id="A4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dx11k66</institution-id><institution>German Centre for Lung Research</institution></institution-wrap> (DZL/BREATH), <city>Hannover</city>, <country country="DE">Germany</country></aff><aff id="A5"><label>5</label>Department of Infectious Diseases, Institute of Clinical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04vgqjj36</institution-id><institution>Sahlgrenska University Hospital</institution></institution-wrap>, <city>Gothenburg</city>, <country country="SE">Sweden</country></aff><aff id="A6"><label>6</label>Department of Respiratory Medicine, Institute of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04vgqjj36</institution-id><institution>Sahlgrenska University Hospital</institution></institution-wrap>, <city>Gothenburg</city>, <country country="SE">Sweden</country></aff><author-notes><corresp id="CR1">
<label>⁋</label><bold>Corresponding author:</bold> Jesper M Magnusson, Department of Respiratory Medicine, Sahlgrenska University Hospital, Bruna stråket 11 SE -413 46 Göteborg, Sweden, X:<ext-link ext-link-type="uri" xlink:href="https://x.com/magnussonMD">@magnussonMD</ext-link></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>12</day><month>06</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>08</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Introduction</title><p id="P1">Freedom from chronic lung allograft dysfunction (CLAD) is a key objective after lung transplantation, yet predicting its onset remains challenging. This study investigated whether early proteomic changes in bronchoalveolar lavage fluid (BALF) can differentiate between patients maintaining stable graft function at 36 months and those developing CLAD within the first year. Additionally, findings were compared to proteomic data from non-transplanted individuals.</p></sec><sec id="S2"><title>Methods</title><p id="P2">BALF samples were collected at one and twelve months post-transplant from 43 lung transplant recipients together with clinical parameters. Proteomic analysis was performed using mass spectrometry with label-free quantification for global protein profiling and heavy-labelled peptides for absolute quantification of mucins and related proteins. Differentially expressed proteins were identified and analyzed through pathway enrichment to explore biological mechanisms associated with CLAD.</p></sec><sec id="S3"><title>Results</title><p id="P3">No significant proteomic differences were detected at one month. By twelve months, 63 proteins were differentially expressed between patients who developed early CLAD and those with stable function. Mucin levels declined in stable patients but remained elevated in both groups compared to healthy controls. Cartilage acidic protein 1 was significantly higher in stable patients at twelve months and correlated with better pulmonary function. Pathway analysis linked several altered proteins in CLAD patients to networks associated with lung injury and remodelling.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">Protein profiles in BALF that resemble those of healthy lungs are associated with sustained graft function, while persistent expression of lung injury markers is associated with early CLAD. This suggests an adaptive process is needed for long-term post-transplant success.</p></sec></abstract></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P5">Lung transplantation (LTx) is a key treatment for end-stage, nonmalignant pulmonary disease when other treatments have failed (<xref ref-type="bibr" rid="R1">1</xref>). Despite its history of over 60 years (<xref ref-type="bibr" rid="R2">2</xref>), the procedure still has worse survival than other solid organ transplants pioneered in the same era (<xref ref-type="bibr" rid="R3">3</xref>). Chronic lung allograft dysfunction (CLAD) is the major cause of death after the first post-operative year, affecting about 50% of recipients within five years (<xref ref-type="bibr" rid="R4">4</xref>). Current understanding of CLAD pathophysiology involves complex interactions of the innate and adaptive immune system and structural tissue remodeling due to repeated lung injury, ultimately leading to allograft failure (<xref ref-type="bibr" rid="R5">5</xref>). Thus, early post-operative CLAD is a major clinical setback, and given the post-operative clinical complexities, the underlying mechanisms are convoluted.</p><p id="P6">LTx presents unique challenges compared to other solid organ transplants due to environmental exposure to particles, pathogens, toxins, and allergens. These interact with the allograft in an immunosuppressed host, increasing the risk of respiratory infections associated with CLAD (<xref ref-type="bibr" rid="R6">6</xref>). Alongside other airway defense mechanisms, the mucus clearance system is essential in protecting the lungs against harmful microbes and infections (<xref ref-type="bibr" rid="R7">7</xref>). Under normal circumstances, ciliary beating transports bundles of mucus strands from submucosal glands and mucus threads from surface cells in an efficient system for moving foreign material out of the lung, keeping the lungs essentially clean (<xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R10">10</xref>). Following infection, mucin secretion, especially MUC5AC is promoted (<xref ref-type="bibr" rid="R11">11</xref>). An attached mucus layer is formed, like other chronic lung diseases such as chronic obstructive pulmonary disease (COPD) (<xref ref-type="bibr" rid="R12">12</xref>). The status of the mucociliary clearance after lung transplantation is likely abnormal, as indicated by reduced mucociliary clearance at least three months after LTx (<xref ref-type="bibr" rid="R13">13</xref>). Also, the transplanted lung is denervated from the lower vagal nerve, which postoperatively impairs the cough reflex for a period of six to twelve months (<xref ref-type="bibr" rid="R14">14</xref>). To what extent the transplanted lung can mimic normal function after transplantation and how the transplantation outcome is reflected in the lung proteome, particularly mucin-related proteins, is unknown.</p><p id="P7">In this observational exploratory study of LTx recipients, patients developing CLAD within the first-year post-transplant (early CLAD; eCLAD) are compared to those alive with stable lung function for at least three years. Using mass spectrometry (MS), protein abundance in bronchoalveolar lavage fluid (BALF) at one (1M) and twelve months (12M) after transplantation is compared. The proteomic results were also compared to healthy non-smokers, healthy smokers and COPD patients (<xref ref-type="bibr" rid="R12">12</xref>) using same heavy-labeled peptides. MS analysis was combined with BALF cellularity and pulmonary function tests (PFT) to identify potential mediators associated with outcomes after LTx.</p></sec><sec id="S6" sec-type="materials | methods"><title>Material and methods</title><sec id="S7"><title>Study design</title><p id="P8">Two patient groups were established from an existing cohort with intensified infection monitoring (<xref ref-type="bibr" rid="R15">15</xref>): LTx recipients exhibiting stable lung function in the first 36 months post-LTx (Stable) and patients who developed CLAD within a year post-LTx (eCLAD). Sample size was determined by availability; no minimum sample size for power was established. BALF samples from 1M and approximately 12M after transplantation were analyzed using MS and evaluated for intra-group (1M versus 12M) and inter-group differences (Stable vs eCLAD). All 12M samples for the eCLAD group were collected after the CLAD diagnosis.</p></sec><sec id="S8"><title>Study subjects</title><p id="P9">Available BALF at 1M and 12M were identified. Patients not matching the Stable or eCLAD criteria with less than five PFTs were excluded, as well as patients with biopsy-verified rejection ≥A2 (<xref ref-type="bibr" rid="R16">16</xref>) or verified infections at time of BALF (<xref ref-type="fig" rid="F1">Figure 1a</xref>). Immunosuppression, follow-up, prophylaxis protocol and clinical analyses are outlined in online supplement. All data were collected from an electronic case report form. The study was approved by the ethical review board (Dnr 791-08). All subjects provided written consent prior to inclusion. All transplants were performed in compliance with the ISHLT ethics statement.</p></sec><sec id="S9"><title>CLAD definition</title><p id="P10">CLAD was defined according to ISHLT consensus; an irreversible 20% loss of FEV1 from the baseline in at least two consecutive PFTs at least three weeks apart, if no other reason for loss of function could be established (<xref ref-type="bibr" rid="R17">17</xref>). Online supplements provide further details.</p></sec><sec id="S10"><title>Proteomics</title><p id="P11">Samples for proteomics were prepared as previously described (<xref ref-type="bibr" rid="R12">12</xref>). Two types of mass-spectrometry analyses were conducted (<xref ref-type="fig" rid="F1">Figure 1a</xref>): untargeted label-free analysis of all the detectable proteins and targeted absolute quantification of 15 mainly mucus or mucin-associated proteins. For targeted absolute quantification a set of heavy-labeled peptides were spiked into the samples during the sample preparation. Spiked in heavy-labeled peptides allowed to compare current results with BALF proteomics from healthy non-smoking, asymptomatic smoking and COPD patients (<xref ref-type="bibr" rid="R12">12</xref>).</p></sec><sec id="S11"><title>Proteomics data analysis</title><p id="P12">Proteomics data were analyzed with the MaxQuant program (v1.5.7.4) (<xref ref-type="bibr" rid="R18">18</xref>). Searches were performed against the human Uniprot protein database (downloaded 2019/12/20) and supplemented with an in-house database containing all the human and mouse mucin sequences (<ext-link ext-link-type="uri" xlink:href="http://www.medkem.gu.se/mucinbiology/databases/">http://www.medkem.gu.se/mucinbiology/databases/</ext-link>). Proteomics data was further analyzed with Perseus software (version 1.5.5.0) (<xref ref-type="bibr" rid="R18">18</xref>) using default parameters. Absolute quantification of proteins that had heavy-labeled standard peptides (<xref ref-type="supplementary-material" rid="SD1">Table E1</xref>) was performed with the Skyline program (version 22.2.0.255) (<xref ref-type="bibr" rid="R19">19</xref>). MS proteomics data were deposited on the Proteome Xchange Consortium (<ext-link ext-link-type="uri" xlink:href="http://proteomecentral.proteomexchange.org">http://proteomecentral.proteomexchange.org</ext-link>) via PRIDE partner repository (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pride/archive/">https://www.ebi.ac.uk/pride/archive/</ext-link>) with dataset identifier PXD044416.</p></sec><sec id="S12"><title>Pathway analysis</title><p id="P13">Significantly different proteins from proteomics data analysis were analyzed using Ingenuity Pathway Analysis (IPA, Qiagen).</p></sec><sec id="S13"><title>Gene ontology mapping</title><p id="P14">Protein-Protein Interaction Networks Functional Enrichment Analysis (STRING, <ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>) web page was used for gene ontology biological process enrichment analysis for significantly changed proteins.</p></sec><sec id="S14"><title>Immunofluorescence</title><p id="P15">The local pathology repository was queried for biopsies corresponding to the bronchoscopies. Available biopsies were stained for MUC5B, MUC5AC, MUC1 and CRTAC1.</p></sec><sec id="S15"><title>Statistical analysis</title><p id="P16">GraphPad Prism 10.4.2 (GraphPad Software, Boston, MA) was used. A p&lt; 0.05 was considered significant. Results are presented as median ± interquartile range (IQR). For comparisons between paired measurements Wilcoxon matched pairs signed rank test was used; for comparisons between two independent measurements Mann-Whitney test was used; for three independent group comparisons, Kruskal-Wallis test with Dunn’s multiple comparisons test was used. For correlations, Spearman’s rank correlation was used. For Volcano plots of proteomic data, visualization of significantly changed proteins was done by a permutation-based false discovery rate (FDR) calculation (&lt;FDR=0.05,S0=0.1).</p></sec></sec><sec id="S16" sec-type="results"><title>Results</title><sec id="S17"><title>Patients and baseline clinical data</title><p id="P17">Samples from 43 patients at two time points were analyzed, 30 in the Stable group and 13 in eCLAD group (<xref ref-type="fig" rid="F1">Figure 1a</xref>). The only significant difference was a higher rate of double-LTx in the Stable group (80% vs. 46%;p&lt;0.05) (<xref ref-type="table" rid="T1">Table 1</xref>). Baseline lung function (% predicted of FEV1(<xref ref-type="bibr" rid="R20">20</xref>)), though variance was lower in the eCLAD group (<xref ref-type="fig" rid="F1">Figure 1b</xref>). PFTs diverged significantly at 9 months (p&lt;0.001) and in subsequent PFTs (<xref ref-type="fig" rid="F1">Figure 1c</xref>). Infections and rejections grade A2+ were tracked monthly (<xref ref-type="fig" rid="F1">Figure 1d</xref>). There were no significant differences during the first 3 months. Over the first year viral (69.2% vs. 33.3%;p&lt;0.05), fungal (30.8% vs. 3.3%;p&lt;0.05) and bacterial (69.2% vs 30%;p&lt;0.05) infections were more frequent in the eCLAD (<xref ref-type="table" rid="T2">Table 2</xref>). However, 6/13 (46%) patients in the eCLAD group had no infections for at least 6 months before the 12M sample. Only two A2 rejections, one per group, were observed. The pattern of infections is similar early post-transplant and diverges after 2-3 months.</p></sec><sec id="S18"><title>Stable patients demonstrated decreasing levels of mucins and mucus-related proteins from 1 to 12 months, whereas levels in eCLAD remain unchanged</title><p id="P18">Mucin-related proteins were quantified by targeted analysis using 56 heavy-labelled peptides for 15 proteins (<xref ref-type="supplementary-material" rid="SD1">Supplementary Tables E1-E2</xref>). Gel-forming airway mucins MUC5B and MUC5AC levels were ~1 fmol/μl in both groups at 1M. Compared to healthy controls from a previous study using the same method and same set of labelled peptides (<xref ref-type="bibr" rid="R12">12</xref>), showed 50-100 times higher mucin levels in Stable and eCLAD patients (<xref ref-type="fig" rid="F2">Figure 2a</xref>). Interestingly, MUC5B levels were similar and MUC5AC levels higher than that of COPD patients. There were no significant changes between 1M to 12M in either group for MUC5AC, MUC5B or MUC1; remaining at higher levels than seen in healthy lungs (<xref ref-type="fig" rid="F2">Figure 2a</xref>). In intergroup comparisons, there were significantly more MUC5AC (p&lt;0.01),MUC5B (p&lt;0.01) and MUC1 (p&lt;0.001) in the eCLAD group at 12M than in the Stable group. Immunostaining of transbronchial biopsies confirmed MUC5AC and MUC5B in both groups (<xref ref-type="fig" rid="F2">Figure 2b-c</xref>). Other mucin-related proteins, significantly increased in COPD patients, including FCGBP, DMBT1, TFF3 and PSCA, showed even higher abundance in transplanted patients (<xref ref-type="fig" rid="F2">Figure 2d</xref> and Figure E1b). In the Stable group, the bacterial binding protein DMBT1 (<xref ref-type="bibr" rid="R21">21</xref>) (p&gt;0.01) and the goblet cell product TFF3 (p&lt;0.05), were decreased, while the goblet cell marker FCGBP was unchanged (<xref ref-type="fig" rid="F2">Figure 2d</xref>). At 12M, levels of DMBT (p&lt;0.05) and TFF3 (p&lt;0.01) were elevated in the eCLAD group compared to Stable (<xref ref-type="fig" rid="F2">Figure 2d</xref>). These results show persistent mucin-associated abnormalities resembling COPD at 1M and 12M.</p></sec><sec id="S19"><title>Stable group develops a distinct proteomic profile in BALF at 12 months</title><p id="P19">MS-based label-free (LFQ) proteomics identified 2,451 proteins, with 721 quantified after filtering proteins based on presence in a minimum of 50% of the samples in at least one group (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table E3</xref>). The Stable group demonstrated differential levels of 155 proteins between 12M and 1M (<xref ref-type="fig" rid="F3">Figure 3a</xref>, left), but no differences in BALF proteins were detected in the eCLAD group (<xref ref-type="fig" rid="F3">Figure 3a</xref>, right). No intergroup differences were found at 1M (<xref ref-type="fig" rid="F3">Figure 3b</xref>, left). However, 63 proteins differed significantly between groups at 12M (<xref ref-type="fig" rid="F3">Figure 3b</xref>, right). Principal component analysis (PCA) confirmed no group separation at 1M, but clear separation at 12M (<xref ref-type="fig" rid="F3">Figure 3c</xref>). Single vs double LTx did not influence PCA or hierarchic clustering (<xref ref-type="supplementary-material" rid="SD1">Figure E2a, E2b</xref>). Altogether, 195 BALF proteins were significantly changed between the 12M versus 1M Stable and 12M Stable versus 12M eCLAD, with 23 overlapping (<xref ref-type="fig" rid="F3">Figure 3d</xref>). Ingenuity Pathway Analysis (IPA) of the 63 intergroup proteins at 12M revealed a "damage of lung" pathway (p=8.01E-5) (<xref ref-type="fig" rid="F3">Figure 3e</xref>). IPA networks for 155 proteins in the Stable group, altered between 1M and 12M, showed reduced activity of functions at 12M, such as inflammatory cell chemotaxis, IL-8 signaling, granulocyte degranulation and killing of bacteria (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure E3a</xref>). Gene ontology analysis showed upregulation of proteins associated with complement activation, negative regulation of endopeptidase activity, post-translational protein modification, and platelet degranulation at 12M (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure E3b</xref>). It identified upregulation of proteins associated with defense response to bacteria, anti-microbial humoral response, toll-like receptor signaling pathway, and blood coagulation at 1M. In the eCLAD group, compared to the Stable group at 12M, proteins associated with defense response to bacterium, anti-microbial humoral response, toll-like receptor signaling pathway, and blood coagulation stood out (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure E3c</xref>). Mediators in the "damage of lung" pathway demonstrated upregulated levels of ICAM1 and SFTPD, and downregulated levels of S100A8, AZU1, CTSG and MPO, CDL5 in Stable group at 12M (<xref ref-type="fig" rid="F3">Figure 3e</xref>). These findings highlight a distinct proteomic profile in Stable group at 12M post LTx.</p></sec><sec id="S20"><title>Lower neutrophil and higher macrophage frequency in the Stable group at 12 months</title><p id="P20">Differential cell-count in BALF showed higher levels of neutrophils at 12M in the eCLAD group compared to Stable group (p &lt; 0.05) (<xref ref-type="fig" rid="F4">Figure 4a</xref>). Macrophages were lower in the eCLAD group at 12M compared to Stable group at 12M (p &lt; 0.01) (<xref ref-type="fig" rid="F4">Figure 4a</xref>). Protein levels determined by MS in BALF reflected cellular infiltrates, where macrophage frequency demonstrated a positive correlation with the macrophage product MRC1 (<xref ref-type="fig" rid="F4">Figure 4b</xref>, left) and neutrophil frequency correlated positively with the neutrophil product MPO (<xref ref-type="fig" rid="F4">Figure 4b</xref>, right). The abundance of mediators identified in the "damage of lung" pathway (ICAM1, SFTPD, A100A8, AZU1, CTSG, MPO) correlated with change in lung function in the Stable and eCLAD groups at 12M (<xref ref-type="fig" rid="F4">Figure 4c</xref>). These findings further support that the changes found in the Stable group are related to a beneficial outcome after LTx.</p></sec><sec id="S21"><title>CRTAC1 levels in BALF correlelate to lung function after lung transplantation</title><p id="P21">CTRAC1, previously linked to healthier lungs (<xref ref-type="bibr" rid="R21">21</xref>), was significantly higher at 12M in the Stable group compared to 1M (p&gt;0.05) and significantly less abundant in the eCLAD group than in Stable group at 12M (p&lt;0.01) (<xref ref-type="fig" rid="F5">Figure 5a</xref>). At 12M, CRTAC1 levels in Stable patients were closer to those in healthy individuals than asymptomatic smokers or COPD patients (<xref ref-type="bibr" rid="R12">12</xref>) (<xref ref-type="fig" rid="F5">Figure 5a</xref>). Biopsies showed less CRTAC1 staining in 1M eCLAD than in the 1M Stable (<xref ref-type="fig" rid="F5">Figure 5b</xref>) despite no significant difference in BALF protein abundance at that time (<xref ref-type="fig" rid="F5">Figure 5a</xref>). CRTAC1 intensity remained weak in the 12M eCLAD biopsies (<xref ref-type="fig" rid="F5">Figure 5c</xref>), with lower signal intensity than in the 1M Stable (<xref ref-type="fig" rid="F5">Figure 5b</xref>). No 12M stable biopsies were available for comparison. Levels of CRTAC1 correlated directly with lung function in the Stable and eCLAD groups at 12M but not at 1M (<xref ref-type="fig" rid="F5">Figure 5d</xref>). Furthermore, the abundance of CRTAC1 in BALF correlated with all the significantly changed proteins annotated as belonging to the "damage of lung" pathway (ICAM1, SFTPD, A100A8, AZU1, CTSG, MPO) (<xref ref-type="fig" rid="F5">Figure 5e</xref>). These findings suggest that the sensitivity in CRTAC1 levels in BALF could help separate Stable patients from eCLAD patients.</p></sec></sec><sec id="S22" sec-type="discussion"><title>Discussion</title><p id="P22">The biological mechanisms of CLAD (<xref ref-type="bibr" rid="R17">17</xref>) and successful lung adaptation post-transplant remains poorly understood. In this study, the Stable and the eCLAD patients showed similar BALF protein profiles at 1M after transplantation but began to diverge after three months post-LTx which possibly reflects early mucosal defense stabilization. By 12M, the Stable group showed BALF proteome normalization, unlike the eCLAD group, which was unchanged between timepoints. This suggests more effective lung adaptation in the Stable group while the eCLAD group do not progress and adapt for unknown reasons.</p><p id="P23">Excluding major confounders, such as infections and grade ≥2 rejection at sampling, strengthens the link between BALF proteome changes and the underlying pathophysiological mechanisms. The high number of single lung transplants (SLTx) reflects common practice at the time (<xref ref-type="bibr" rid="R22">22</xref>). SLTx is a risk factor for shorter CLAD-free survival without differences in the number of infections (<xref ref-type="bibr" rid="R23">23</xref>). No significant difference in best PFT and the ≥20% decline in the eCLAD group suggests intrinsic allograft issues rather than procedural differences. This is supported by the lack of distinction between SLTx and double LTx in BALF proteome.</p><p id="P24">Due to study design, we cannot conclude whether the higher number of infections in the eCLAD group impedes adaptation or result from it. However, infection rates did not differ during the first three months. There is no difference in immunosuppression nor missed through-calcineurin inhibitor levels, which excludes treatment differences. The BALF cell reflects known CLAD patterns with more neutrophils than macrophages (<xref ref-type="bibr" rid="R24">24</xref>). The observed period (1M-12M) overlaps with delayed mucociliary clearance (<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>). Retarded mucus clearance is a protection mechanism that limits bacteria reaching the epithelial cells (<xref ref-type="bibr" rid="R12">12</xref>), suggesting that mucus system dysfunction may contribute to the infection pattern.</p><p id="P25">Lower MUC5AC, MUC5B and MUC1 levels in the Stable group at 12M support a role for mucus clearance in eCLAD development. However, both groups showed mucin levels more like the COPD than non-COPD controls from our previous study using the same method (<xref ref-type="bibr" rid="R12">12</xref>). This indicates ongoing stress even in the Stable allografts. The impact of pre- and post-operative ventilation on 1M is unclear, though MUC5AC is linked to ventilator-induced lung injury (<xref ref-type="bibr" rid="R25">25</xref>). High MUC5B and MUC5AC mucins in biopsies from both groups further support that the transplanted lungs differ from healthy controls (<xref ref-type="bibr" rid="R12">12</xref>). Previous studies, also report elevated mucin levels in BALF from CLAD patients with high MUC5B levels associated with shorter post-diagnosis survival (<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R27">27</xref>).</p><p id="P26">Overall, the protein levels of the 12M Stable group stood out compared to the other groups (1M Stable, 1M eCLAD and 12M eCLAD). The network identified through IPA contained proteins associated with acute lung injury (MPO, CTSG, ICAM1) (<xref ref-type="bibr" rid="R28">28</xref>), neutrophil activity (MPO, CTSG, S100A8) (28), and emphysema (SFPTd) (<xref ref-type="bibr" rid="R29">29</xref>). In support of neutrophil activity identified in the network, S100A8/A9 proteins have been associated with CLAD (<xref ref-type="bibr" rid="R30">30</xref>), MPO is associated with neutrophil extracellular traps (<xref ref-type="bibr" rid="R31">31</xref>) and ELANE, which is also elevated, is central in the process of forming these (<xref ref-type="bibr" rid="R32">32</xref>). Interestingly, all these proteins have been identified as possible therapeutic targets (<xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R37">37</xref>). The direct correlation between protein levels in BALF and pulmonary function is a further indication of the central role of ICAM1, SFPTD, S100A8, AZU1, CTSG and MPO in post-transplant lung adaptation and is interesting in the context of recent observations highlighting the importance of best post operative-lung function (<xref ref-type="bibr" rid="R38">38</xref>). The finding also mechanistically supports early post-operative introduction of Azithromycin for neutrophil modulation (<xref ref-type="bibr" rid="R39">39</xref>).</p><p id="P27">CRTAC1, a glycosylated extracellular matrix protein originally found in human cartilage (<xref ref-type="bibr" rid="R40">40</xref>) but also produced by type 2 alveolar cells (<xref ref-type="bibr" rid="R41">41</xref>), was increased over time in the Stable group. While its function in the lung is still unknown, CRTAC1 has been negatively associated with lung fibrosis (<xref ref-type="bibr" rid="R21">21</xref>). In this study it is strongly correlated with the "damage of lung" network and lung function for both the eCLAD and the Stable groups. This suggests a central mechanistic role in lung health, and a potential for further exploration as a biomarker.</p><p id="P28">This study has limitations. Although based on a prospective cohort, the retrospective design may introduce hidden bias and preclude mechanistic conclusions. Most patients received cyclosporin, now considered a suboptimal treatment option after lung transplantation (<xref ref-type="bibr" rid="R42">42</xref>), and the small number of CLAD patients limits phenotype-specific analysis. Strengths of the study are the very well-defined infection-surveilled prospective cohort and the clear definition of confounder-depleted grouping. Furthermore, the general protocolized surveillance reduces risk of group-dependent data collection bias.</p><p id="P29">In conclusion, this study suggests that stable, long-term surviving allografts undergo an adaptation towards a healthier state. However, the mucin proteomic profile, affecting first-line infection defense, remains like that of COPD lungs, even in clinically stable allografts. This suggests that even allografts with excellent function and CLAD-free survival are under functional stress corresponding to a chronic lung disease. We found that the functional status of the transplanted lung can be directly correlated to the proteins in the identified lung damage network. Notably, CRTAC1 correlates with all these processes, making it an interesting protein in association with pulmonary stability.</p><p id="P30">Our findings reveal a gap between the transplanted lung and healthy lungs, underscoring the need for further improvement of allograft management pre-, peri-, and post-operatively to enhance transplant outcomes. The correlation of functional status with closely interacting proteins in the damage of lung network suggests approaches for mechanistic and therapeutic research to be validated in future prospective studies. While reversing CLAD remains a major goal for the lung transplant community, the current study supports that research aiming to explore, improve and preserve best initial lung function should be a parallel priority to advance lung transplantation outcomes.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental information</label><media xlink:href="EMS206370-supplement-Supplemental_information.pdf" mimetype="application" mime-subtype="pdf" id="d92aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary_Figure</label><media xlink:href="EMS206370-supplement-Supplementary_Figure.pdf" mimetype="application" mime-subtype="pdf" id="d92aAcEcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S23"><title>Acknowledgements</title><p>The following sources funded the study: The project has been supported by the Gothenburg medical society (GLS-986352) Knut and Alice Wallenberg Foundation (2017.0028), Swedish Research Council (2023-02474), the European Research Council ERC (101100663, 694181), IngaBritt and Arne Lundberg Foundation (2018-0117), Västra Götalandsregionen (ALFGBG-440741, -236501, -995932, -942865(JMM), Wilhelm and Martina Lundgren’s Foundation. The Swedish Heart-Lung Foundation (20190311, 20200680, 20220404 (AE); 20210377, 20230413 (GCH) +JMM); 20220466 JMM), Lederhausen’s Center for CF Research at Univ. Gothenburg, the Wenner-Gren Foundations (KJ) and Herman Krefting Foundation (KJ)), Sahlgrenska, NHV -967493.</p><p>The following disclosures are reported: LA,KJ - no disclosures, AE – Shareholder Mucolife Therpeutics, MG – Speakers fee, Therakos (UK) DSMB E-CLAD study, TP – Shareholder and CEO Mucolife Theraputics, – Mucolife Therapeutics, JW - No disclosures, GCH – Shareholder and CSO, Mucolife Therapeutics, JMM – Speakers Fee Boehringer Ingelheim, AstraZeneca, Takada Pharma, GlaxoSmithKline, Mallinckrodt, Vicore Pharma; Advisory Board - Boehringer Ingelheim; Boardmember (unpaid) Swedish pulmonary fibrosis registry, Scandinavian Heart and Lung group.</p><p>In addition to this we wish to acknowledge the work of the staff of the lung transplant department and the staff of the viral detection laboratory at Sahlgrenska University for their support of the current study.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>LTx</term><def><p>Lungtransplantation</p></def></def-item><def-item><term>CLAD</term><def><p>Chronic Lung Allograft Dysfunction</p></def></def-item><def-item><term>COPD</term><def><p>Chronic obstructive lung disease</p></def></def-item><def-item><term>eCLAD</term><def><p>Early CLAD (group denomination)</p></def></def-item><def-item><term>1M</term><def><p>One Month</p></def></def-item><def-item><term>12M</term><def><p>12 Months</p></def></def-item><def-item><term>BALF</term><def><p>Bronchoalveolar Lavage Fluid</p></def></def-item><def-item><term>PFT</term><def><p>Pulmonary Function Test</p></def></def-item><def-item><term>FEV1</term><def><p>Forced expiratory volume during the first second</p></def></def-item><def-item><term>FDR</term><def><p>False discovery rate</p></def></def-item></def-list></glossary><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leard</surname><given-names>LE</given-names></name><name><surname>Holm</surname><given-names>AM</given-names></name><name><surname>Valapour</surname><given-names>M</given-names></name><name><surname>Glanville</surname><given-names>AR</given-names></name><name><surname>Attawar</surname><given-names>S</given-names></name><name><surname>Aversa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation</article-title><source>J Heart Lung Transplant</source><year>2021</year><volume>40</volume><issue>11</issue><fpage>1349</fpage><lpage>79</lpage><pub-id pub-id-type="pmcid">PMC8979471</pub-id><pub-id pub-id-type="pmid">34419372</pub-id><pub-id pub-id-type="doi">10.1016/j.healun.2021.07.005</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panchabhai</surname><given-names>TS</given-names></name><name><surname>Chaddha</surname><given-names>U</given-names></name><name><surname>McCurry</surname><given-names>KR</given-names></name><name><surname>Bremner</surname><given-names>RM</given-names></name><name><surname>Mehta</surname><given-names>AC</given-names></name></person-group><article-title>Historical perspectives of lung transplantation: connecting the dots</article-title><source>J Thorac Dis</source><year>2018</year><volume>10</volume><issue>7</issue><fpage>4516</fpage><lpage>31</lpage><pub-id pub-id-type="pmcid">PMC6105978</pub-id><pub-id pub-id-type="pmid">30174905</pub-id><pub-id pub-id-type="doi">10.21037/jtd.2018.07.06</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thabut</surname><given-names>G</given-names></name><name><surname>Mal</surname><given-names>H</given-names></name></person-group><article-title>Outcomes after lung transplantation</article-title><source>J Thorac Dis</source><year>2017</year><volume>9</volume><issue>8</issue><fpage>2684</fpage><lpage>91</lpage><pub-id pub-id-type="pmcid">PMC5594127</pub-id><pub-id pub-id-type="pmid">28932576</pub-id><pub-id pub-id-type="doi">10.21037/jtd.2017.07.85</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perch</surname><given-names>M</given-names></name><name><surname>Hayes</surname><given-names>D</given-names></name><name><surname>Cherikh</surname><given-names>WS</given-names></name><name><surname>Zuckermann</surname><given-names>A</given-names></name><name><surname>Harhay</surname><given-names>MO</given-names></name><name><surname>Hsich</surname><given-names>E</given-names></name><etal/></person-group><article-title>The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease</article-title><source>J Heart Lung Transplant</source><year>2022</year><volume>41</volume><issue>10</issue><fpage>1335</fpage><lpage>47</lpage><pub-id pub-id-type="pmcid">PMC10257980</pub-id><pub-id pub-id-type="pmid">36050206</pub-id><pub-id pub-id-type="doi">10.1016/j.healun.2022.08.007</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>S</given-names></name><name><surname>Milross</surname><given-names>L</given-names></name><name><surname>Filby</surname><given-names>AJ</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>AJ</given-names></name></person-group><article-title>Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle</article-title><source>Eur Respir Rev</source><year>2022</year><volume>31</volume><issue>165</issue><pub-id pub-id-type="pmcid">PMC9724884</pub-id><pub-id pub-id-type="pmid">35896274</pub-id><pub-id pub-id-type="doi">10.1183/16000617.0060-2022</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregson</surname><given-names>AL</given-names></name></person-group><article-title>Infectious Triggers of Chronic Lung Allograft Dysfunction</article-title><source>Curr Infect Dis Rep</source><year>2016</year><volume>18</volume><issue>7</issue><fpage>21</fpage><pub-id pub-id-type="pmcid">PMC7089243</pub-id><pub-id pub-id-type="pmid">27221821</pub-id><pub-id pub-id-type="doi">10.1007/s11908-016-0529-6</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridley</surname><given-names>C</given-names></name><name><surname>Thornton</surname><given-names>DJ</given-names></name></person-group><article-title>Mucins: the frontline defence of the lung</article-title><source>Biochem Soc Trans</source><year>2018</year><volume>46</volume><issue>5</issue><fpage>1099</fpage><lpage>106</lpage><pub-id pub-id-type="pmcid">PMC6195635</pub-id><pub-id pub-id-type="pmid">30154090</pub-id><pub-id pub-id-type="doi">10.1042/BST20170402</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ermund</surname><given-names>A</given-names></name><name><surname>Meiss</surname><given-names>LN</given-names></name><name><surname>Dolan</surname><given-names>B</given-names></name><name><surname>Jaudas</surname><given-names>F</given-names></name><name><surname>Ewaldsson</surname><given-names>L</given-names></name><name><surname>Bahr</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mucus threads from surface goblet cells clear particles from the airways</article-title><source>Respir Res</source><year>2021</year><volume>22</volume><issue>1</issue><fpage>303</fpage><pub-id pub-id-type="pmcid">PMC8620232</pub-id><pub-id pub-id-type="pmid">34823518</pub-id><pub-id pub-id-type="doi">10.1186/s12931-021-01898-3</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trillo-Muyo</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>HE</given-names></name><name><surname>Recktenwald</surname><given-names>CV</given-names></name><name><surname>Ermund</surname><given-names>A</given-names></name><name><surname>Ridley</surname><given-names>C</given-names></name><name><surname>Meiss</surname><given-names>LN</given-names></name><etal/></person-group><article-title>Granule-stored MUC5B mucins are packed by the non-covalent formation of N-terminal head-to-head tetramers</article-title><source>J Biol Chem</source><year>2018</year><volume>293</volume><issue>15</issue><fpage>5746</fpage><lpage>54</lpage><pub-id pub-id-type="pmcid">PMC5900763</pub-id><pub-id pub-id-type="pmid">29440393</pub-id><pub-id pub-id-type="doi">10.1074/jbc.RA117.001014</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ermund</surname><given-names>A</given-names></name><name><surname>Meiss</surname><given-names>LN</given-names></name><name><surname>Rodriguez-Pineiro</surname><given-names>AM</given-names></name><name><surname>Bahr</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>HE</given-names></name><name><surname>Trillo-Muyo</surname><given-names>S</given-names></name><etal/></person-group><article-title>The normal trachea is cleaned by MUC5B mucin bundles from the submucosal glands coated with the MUC5AC mucin</article-title><source>Biochem Biophys Res Commun</source><year>2017</year><volume>492</volume><issue>3</issue><fpage>331</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC5596833</pub-id><pub-id pub-id-type="pmid">28859985</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.08.113</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>Airway Epithelial Differentiation and Mucociliary Clearance</article-title><source>Ann Am Thorac Soc</source><year>2018</year><volume>15</volume><issue>Suppl 3</issue><fpage>S143</fpage><lpage>S8</lpage><pub-id pub-id-type="pmcid">PMC6322033</pub-id><pub-id pub-id-type="pmid">30431340</pub-id><pub-id pub-id-type="doi">10.1513/AnnalsATS.201802-128AW</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Blanco</surname><given-names>JA</given-names></name><name><surname>Fakih</surname><given-names>D</given-names></name><name><surname>Arike</surname><given-names>L</given-names></name><name><surname>Rodriguez-Pineiro</surname><given-names>AM</given-names></name><name><surname>Martinez-Abad</surname><given-names>B</given-names></name><name><surname>Skansebo</surname><given-names>E</given-names></name><etal/></person-group><article-title>Attached stratified mucus separates bacteria from the epithelial cells in COPD lungs</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><issue>17</issue><pub-id pub-id-type="pmcid">PMC6171804</pub-id><pub-id pub-id-type="pmid">30185674</pub-id><pub-id pub-id-type="doi">10.1172/jci.insight.120994</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryadinata</surname><given-names>R</given-names></name><name><surname>Levin</surname><given-names>K</given-names></name><name><surname>Holsworth</surname><given-names>L</given-names></name><name><surname>Paraskeva</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>P</given-names></name></person-group><article-title>Airway cilia recovery post lung transplantation</article-title><source>Immun Inflamm Dis</source><year>2021</year><volume>9</volume><issue>4</issue><fpage>1716</fpage><lpage>23</lpage><pub-id pub-id-type="pmcid">PMC8589372</pub-id><pub-id pub-id-type="pmid">34547188</pub-id><pub-id pub-id-type="doi">10.1002/iid3.527</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>AG</given-names></name><name><surname>Myers</surname><given-names>AC</given-names></name></person-group><article-title>Cough reflex in lung transplant recipients</article-title><source>Lung</source><year>2012</year><volume>190</volume><issue>1</issue><fpage>23</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22139551</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnusson</surname><given-names>J</given-names></name><name><surname>Westin</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>LM</given-names></name><name><surname>Lindh</surname><given-names>M</given-names></name><name><surname>Brittain-Long</surname><given-names>R</given-names></name><name><surname>Norden</surname><given-names>R</given-names></name><etal/></person-group><article-title>Viral Respiratory Tract Infection During the First Postoperative Year Is a Risk Factor for Chronic Rejection After Lung Transplantation</article-title><source>Transplant Direct</source><year>2018</year><volume>4</volume><issue>8</issue><fpage>e370</fpage><pub-id pub-id-type="pmcid">PMC6092179</pub-id><pub-id pub-id-type="pmid">30255130</pub-id><pub-id pub-id-type="doi">10.1097/TXD.0000000000000808</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Fishbein</surname><given-names>MC</given-names></name><name><surname>Snell</surname><given-names>GI</given-names></name><name><surname>Berry</surname><given-names>GJ</given-names></name><name><surname>Boehler</surname><given-names>A</given-names></name><name><surname>Burke</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection</article-title><source>J Heart Lung Transplant</source><year>2007</year><volume>26</volume><issue>12</issue><fpage>1229</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">18096473</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verleden</surname><given-names>GM</given-names></name><name><surname>Glanville</surname><given-names>AR</given-names></name><name><surname>Lease</surname><given-names>ED</given-names></name><name><surname>Fisher</surname><given-names>AJ</given-names></name><name><surname>Calabrese</surname><given-names>F</given-names></name><name><surname>Corris</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT</article-title><source>J Heart Lung Transplant</source><year>2019</year><volume>38</volume><issue>5</issue><fpage>493</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">30962148</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title><source>Nat Biotechnol</source><year>2008</year><volume>26</volume><issue>12</issue><fpage>1367</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">19029910</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>T</given-names></name></person-group><article-title>Gentle Introduction to the Statistical Foundations of False Discovery Rate in Quantitative Proteomics</article-title><source>J Proteome Res</source><year>2018</year><volume>17</volume><issue>1</issue><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">29067805</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>BG</given-names></name><name><surname>Stocks</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>GL</given-names></name><name><surname>Culver</surname><given-names>B</given-names></name><name><surname>Steenbruggen</surname><given-names>I</given-names></name><name><surname>Carter</surname><given-names>KW</given-names></name><etal/></person-group><article-title>The Global Lung Function Initiative (GLI) Network: bringing the world's respiratory reference values together</article-title><source>Breathe (Sheff)</source><year>2017</year><volume>13</volume><issue>3</issue><fpage>e56</fpage><lpage>e64</lpage><pub-id pub-id-type="pmcid">PMC5607614</pub-id><pub-id pub-id-type="pmid">28955406</pub-id><pub-id pub-id-type="doi">10.1183/20734735.012717</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>CH</given-names></name><name><surname>Simon</surname><given-names>LM</given-names></name><name><surname>Leuschner</surname><given-names>G</given-names></name><name><surname>Ansari</surname><given-names>M</given-names></name><name><surname>Schniering</surname><given-names>J</given-names></name><name><surname>Geyer</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers</article-title><source>EMBO Mol Med</source><year>2021</year><volume>13</volume><issue>4</issue><elocation-id>e12871</elocation-id><pub-id pub-id-type="pmcid">PMC8033531</pub-id><pub-id pub-id-type="pmid">33650774</pub-id><pub-id pub-id-type="doi">10.15252/emmm.202012871</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>DC</given-names></name><name><surname>Perch</surname><given-names>M</given-names></name><name><surname>Zuckermann</surname><given-names>A</given-names></name><name><surname>Cherikh</surname><given-names>WS</given-names></name><name><surname>Harhay</surname><given-names>MO</given-names></name><name><surname>Hayes</surname><given-names>D</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics</article-title><source>J Heart Lung Transplant</source><year>2021</year><volume>40</volume><issue>10</issue><fpage>1060</fpage><lpage>72</lpage><pub-id pub-id-type="pmcid">PMC10282986</pub-id><pub-id pub-id-type="pmid">34419370</pub-id><pub-id pub-id-type="doi">10.1016/j.healun.2021.07.015</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Bian</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Bilateral Lung Transplantation Provides Better Long-term Survival and Pulmonary Function Than Single Lung Transplantation: A Systematic Review and Meta-analysis</article-title><source>Transplantation</source><year>2019</year><volume>103</volume><issue>12</issue><fpage>2634</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">31283687</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>S</given-names></name><name><surname>Filby</surname><given-names>AJ</given-names></name><name><surname>Vos</surname><given-names>R</given-names></name><name><surname>Fisher</surname><given-names>AJ</given-names></name></person-group><article-title>Effector immune cells in chronic lung allograft dysfunction: A systematic review</article-title><source>Immunology</source><year>2022</year><volume>166</volume><issue>1</issue><fpage>17</fpage><lpage>37</lpage><pub-id pub-id-type="pmcid">PMC9426626</pub-id><pub-id pub-id-type="pmid">35137398</pub-id><pub-id pub-id-type="doi">10.1111/imm.13458</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koeppen</surname><given-names>M</given-names></name><name><surname>McNamee</surname><given-names>EN</given-names></name><name><surname>Brodsky</surname><given-names>KS</given-names></name><name><surname>Aherne</surname><given-names>CM</given-names></name><name><surname>Faigle</surname><given-names>M</given-names></name><name><surname>Downey</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Detrimental role of the airway mucin Muc5ac during ventilator-induced lung injury</article-title><source>Mucosal Immunol</source><year>2013</year><volume>6</volume><issue>4</issue><fpage>762</fpage><lpage>75</lpage><pub-id pub-id-type="pmcid">PMC3890100</pub-id><pub-id pub-id-type="pmid">23187315</pub-id><pub-id pub-id-type="doi">10.1038/mi.2012.114</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosanam</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Batruch</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Keshavjee</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction</article-title><source>Clin Biochem</source><year>2012</year><volume>45</volume><issue>3</issue><fpage>223</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">22206736</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>L</given-names></name><name><surname>Moshkelgosha</surname><given-names>S</given-names></name><name><surname>Huszti</surname><given-names>E</given-names></name><name><surname>Hunter</surname><given-names>S</given-names></name><name><surname>Renaud-Picard</surname><given-names>B</given-names></name><name><surname>Berra</surname><given-names>G</given-names></name><etal/></person-group><article-title>Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction</article-title><source>J Heart Lung Transplant</source><year>2023</year><volume>42</volume><issue>8</issue><fpage>1152</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">36963446</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Andrographolide Sulfonate Attenuates Acute Lung Injury by Reducing Expression of Myeloperoxidase and Neutrophil-Derived Proteases in Mice</article-title><source>Front Physiol</source><year>2018</year><volume>9</volume><fpage>939</fpage><pub-id pub-id-type="pmcid">PMC6107831</pub-id><pub-id pub-id-type="pmid">30174607</pub-id><pub-id pub-id-type="doi">10.3389/fphys.2018.00939</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>H</given-names></name><name><surname>Kuroki</surname><given-names>Y</given-names></name></person-group><article-title>The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity</article-title><source>Mol Immunol</source><year>2005</year><volume>42</volume><issue>3</issue><fpage>279</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">15589315</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakata</surname><given-names>K</given-names></name><name><surname>Okazaki</surname><given-names>M</given-names></name><name><surname>Kawana</surname><given-names>S</given-names></name><name><surname>Kubo</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>D</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><etal/></person-group><article-title>S100A8/A9 as a prognostic biomarker in lung transplantation</article-title><source>Clin Transplant</source><year>2023</year><volume>37</volume><issue>9</issue><elocation-id>e15006</elocation-id><pub-id pub-id-type="pmid">37115007</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonneau</surname><given-names>S</given-names></name><name><surname>Landry</surname><given-names>C</given-names></name><name><surname>Begin</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>D</given-names></name><name><surname>Villeneuve</surname><given-names>L</given-names></name><name><surname>Clavet-Lanthier</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Correlation between Neutrophil Extracellular Traps (NETs) Expression and Primary Graft Dysfunction Following Human Lung Transplantation</article-title><source>Cells</source><year>2022</year><volume>11</volume><issue>21</issue><pub-id pub-id-type="pmcid">PMC9656095</pub-id><pub-id pub-id-type="pmid">36359815</pub-id><pub-id pub-id-type="doi">10.3390/cells11213420</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps in homeostasis and disease</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>235</fpage><pub-id pub-id-type="pmcid">PMC11415080</pub-id><pub-id pub-id-type="pmid">39300084</pub-id><pub-id pub-id-type="doi">10.1038/s41392-024-01933-x</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burster</surname><given-names>T</given-names></name><name><surname>Macmillan</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>T</given-names></name><name><surname>Boehm</surname><given-names>BO</given-names></name><name><surname>Mellins</surname><given-names>ED</given-names></name></person-group><article-title>Cathepsin G: roles in antigen presentation and beyond</article-title><source>Mol Immunol</source><year>2010</year><volume>47</volume><issue>4</issue><fpage>658</fpage><lpage>65</lpage><pub-id pub-id-type="pmcid">PMC4159238</pub-id><pub-id pub-id-type="pmid">19910052</pub-id><pub-id pub-id-type="doi">10.1016/j.molimm.2009.10.003</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesaro</surname><given-names>A</given-names></name><name><surname>Anceriz</surname><given-names>N</given-names></name><name><surname>Plante</surname><given-names>A</given-names></name><name><surname>Page</surname><given-names>N</given-names></name><name><surname>Tardif</surname><given-names>MR</given-names></name><name><surname>Tessier</surname><given-names>PA</given-names></name></person-group><article-title>An inflammation loop orchestrated by S100A9 and calprotectin is critical for development of arthritis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>9</issue><elocation-id>e45478</elocation-id><pub-id pub-id-type="pmcid">PMC3445527</pub-id><pub-id pub-id-type="pmid">23029038</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0045478</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senjor</surname><given-names>E</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name><name><surname>Nanut</surname><given-names>MP</given-names></name></person-group><article-title>Cysteine Cathepsins as Therapeutic Targets in Immune Regulation and Immune Disorders</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><issue>2</issue><pub-id pub-id-type="pmcid">PMC9953096</pub-id><pub-id pub-id-type="pmid">36831012</pub-id><pub-id pub-id-type="doi">10.3390/biomedicines11020476</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaikijurajai</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>WHW</given-names></name></person-group><article-title>Myeloperoxidase: a potential therapeutic target for coronary artery disease</article-title><source>Expert Opin Ther Targets</source><year>2020</year><volume>24</volume><issue>7</issue><fpage>695</fpage><lpage>705</lpage><pub-id pub-id-type="pmcid">PMC7387188</pub-id><pub-id pub-id-type="pmid">32336171</pub-id><pub-id pub-id-type="doi">10.1080/14728222.2020.1762177</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriksen</surname><given-names>PA</given-names></name></person-group><article-title>The potential of neutrophil elastase inhibitors as anti-inflammatory therapies</article-title><source>Curr Opin Hematol</source><year>2014</year><volume>21</volume><issue>1</issue><fpage>23</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24241342</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>MB</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Alnababteh</surname><given-names>M</given-names></name><name><surname>Ponor</surname><given-names>L</given-names></name><name><surname>P</surname><given-names>DS</given-names></name><name><surname>Mathew</surname><given-names>J</given-names></name><etal/></person-group><article-title>Baseline Lung Allograft Dysfunction After Bilateral Lung Transplantation Is Associated With an Increased Risk of Death: Results From a Multicenter Cohort Study</article-title><source>Transplant Direct</source><year>2024</year><volume>10</volume><issue>7</issue><elocation-id>e1669</elocation-id><pub-id pub-id-type="pmcid">PMC11216668</pub-id><pub-id pub-id-type="pmid">38953039</pub-id><pub-id pub-id-type="doi">10.1097/TXD.0000000000001669</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristeto Porras</surname><given-names>M</given-names></name><name><surname>Mora Cuesta</surname><given-names>VM</given-names></name><name><surname>Iturbe Fernandez</surname><given-names>D</given-names></name><name><surname>Tello Mena</surname><given-names>S</given-names></name><name><surname>Alonso Lecue</surname><given-names>P</given-names></name><name><surname>Sanchez Moreno</surname><given-names>L</given-names></name><etal/></person-group><article-title>Early onset of azithromycin to prevent CLAD in lung transplantation: Promising results of a retrospective single centre experience</article-title><source>Clin Transplant</source><year>2023</year><volume>37</volume><issue>1</issue><elocation-id>e14832</elocation-id><pub-id pub-id-type="pmid">36217992</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steck</surname><given-names>E</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Pelttari</surname><given-names>K</given-names></name><name><surname>Kadel</surname><given-names>S</given-names></name><name><surname>Kalbacher</surname><given-names>H</given-names></name><name><surname>Richter</surname><given-names>W</given-names></name></person-group><article-title>Chondrocyte secreted CRTAC1: a glycosylated extracellular matrix molecule of human articular cartilage</article-title><source>Matrix Biol</source><year>2007</year><volume>26</volume><issue>1</issue><fpage>30</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17074475</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>PL</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Chapin</surname><given-names>C</given-names></name><name><surname>Allen</surname><given-names>L</given-names></name><name><surname>Segal</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Regulated gene expression in cultured type II cells of adult human lung</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2010</year><volume>299</volume><issue>1</issue><fpage>L36</fpage><lpage>50</lpage><pub-id pub-id-type="pmcid">PMC2904098</pub-id><pub-id pub-id-type="pmid">20382749</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00427.2009</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellgren</surname><given-names>G</given-names></name><name><surname>Lund</surname><given-names>TK</given-names></name><name><surname>Raivio</surname><given-names>P</given-names></name><name><surname>Leuckfeld</surname><given-names>I</given-names></name><name><surname>Svahn</surname><given-names>J</given-names></name><name><surname>Holmberg</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial</article-title><source>Lancet Respir Med</source><year>2024</year><volume>12</volume><issue>1</issue><fpage>34</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">37703908</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" orientation="portrait" position="float"><caption><title>Take home message</title></caption><p>Stable lung transplants show better proteomic adaptation than eCLAD, yet both retain COPD-like mucus profiles. CRTAC1 and lung damage proteins correlate with function, highlighting targets to improve long-term graft health and early function preservation.</p></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>The eCLAD group of patients have respiratory infections at a later stage after lung transplantation compared to the Stable group.</title><p><bold>A:</bold> Selection of study subjects for mass spectrometry (MS)-based proteomics analysis of bronchoalveolar lavage (BAL) fluid. <bold>B:</bold> Baseline lung function (measured by % expected of forced expiratory volume in 1 second (FEV1)) of Stable and early CLAD (eCLAD) groups. Normal range indicated in grey. <bold>C:</bold> Lung function measurement (FEV1) over time. <bold>D:</bold> Respiratory infections after lung transplantation (LTx) in all Stable and eCLAD patients. Mann-Whitney U test was used for statistical analysis in B and C. ***p &lt; 0.001, and ****p &lt; 0.0001 for significance.</p></caption><graphic xlink:href="EMS206370-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Airway mucins are increased in eCLAD patients at 12 months after lung transplantation.</title><p><bold>A:</bold> Absolute quantification of MUC5AC, MUC5B and MUC1 by mass spectrometry in Stable and early CLAD (eCLAD) patients at 1 month (1M) and 12 months (12M) after lung transplantation. Mucin levels are matched to a reference cohort of non-smokers (NS), asymptomatic smokers (AS) and patients with chronic obstructive pulmonary disease (COPD) from a previous study (<xref ref-type="bibr" rid="R12">12</xref>). Bronchial biopsies (patients marked with bold circles on A) stained by immunofluorescence to visualize mucin-producing goblet cells (GC) in a Stable patient <bold>(B)</bold> and an eCLAD patient <bold>(C). D:</bold> Absolute quantification of mucin-related proteins in bronchoalveolar lavage fluid by MS from Stable and eCLAD patients at 1M and 12M compared to the reference cohort from a previous study (<xref ref-type="bibr" rid="R12">12</xref>). For comparisons between paired measurements Wilcoxon matched pairs signed rank test was used; for comparisons between two independent measurements Mann-Whitney test was used; for three independent group comparisons, Kruskal-Wallis test with Dunn’s multiple comparisons test was used. **p &lt; 0.01 and ***p &lt; 0.001 for significance.</p></caption><graphic xlink:href="EMS206370-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>The BALF proteome changes over time in Stable patients, but not in eCLAD patients, and identifies proteins associated with lung damage.</title><p><bold>A:</bold> Volcano plots demonstrating differential levels of bronchoalveolar lavage fluid (BALF) proteins in Stable and eCLAD (early CLAD) groups at 1 month (1M) versus 12 months (12M) after lung transplantation. <bold>B:</bold> Volcano plots demonstrating differential levels of BALF proteins at 1M and 12M in Stable versus eCLAD groups. <bold>C:</bold> Principal component analysis of BALF proteome in Stable and eCLAD groups at 1M (above) and 12M (below). For clarity, 1M and 12M samples have been presented on separate plots. <bold>D:</bold> Venn diagram of significantly altered BALF proteins in Stable group at 1M versus 12M, and eCLAD group at 12M versus Stable at 12M. The 23 common proteins are shown in the heatmap. <bold>E:</bold> IPA analysis of all differential BALF proteins in eCLAD at 12M versus Stable at 12M identifies damage of lung network. Key proteins are shown in the heatmap with actual measurement (left) and IPA predicted direction for lung damage (right). The heatmap key (D) corresponds to Log2 ratios for D and E.</p></caption><graphic xlink:href="EMS206370-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Lung damage-markers correlate with improved lung function in the Stable group.</title><p><bold>A:</bold> Differential cell count of bronchoalveolar lavage fluid (BALF) cells at 1 month (1M) and 12-months (12M) after lung transplantation in Stable and early CLAD (eCLAD) patients. <bold>B:</bold> Spearman correlation between BALF macrophage frequency and level of macrophage-associated protein MCR1 in BALF (left), and BALF neutrophil frequency and level of neutrophil-associated protein MPO in BALF (right). <bold>C:</bold> Spearman correlation between lung damage-associated proteins in BALF and lung function measurement by % expected forced expiratory volume in 1 second (FEV1). For comparisons between paired measurements Wilcoxon matched pairs signed rank test was used; for comparisons between two independent measurements Mann-Whitney test was used in A. *p &lt; 0.05, and **p &lt; 0.01 for significance.</p></caption><graphic xlink:href="EMS206370-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>CRTAC1 levels are increased in Stable patients at 12 months after lung transplantation and correlate with lung function measurements.</title><p><bold>A:</bold> CRTAC1 levels in bronchoalveolar lavage fluid (BALF) determined by mass spectrometry in Stable and early CLAD (eCLAD) patients at 1 month (1M) and 12 months (12M) after lung transplantation, compared to a reference cohort of non-smokers (NS), asymptomatic smokers (AS) and patients with chronic obstructive pulmonary disease (COPD) from a previous study (12). CRTAC1 stained by immunofluorescence in bronchial biopsies obtained at 1M <bold>(B)</bold> and 12M <bold>(C)</bold> (patients marked with bold circles on A). <bold>D:</bold> Spearman correlation between CRTAC1 levels in BALF and lung function measurement by % expected forced expiratory volume in 1 second (FEV1). <bold>E:</bold> Spearman correlation between CRTAC1 levels in BALF and levels of lung damage-associated proteins in BALF. For comparisons between paired measurements Wilcoxon matched pairs signed rank test was used; for comparisons between two independent measurements Mann-Whitney test was used; for three independent group comparisons, Kruskal-Wallis test with Dunn’s multiple comparisons test was used on A. *p &lt; 0.05, **p &lt; 0.01 for significance</p></caption><graphic xlink:href="EMS206370-f005"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Baseline Characteristics of Included Patients</title></caption><table frame="box" rules="all"><thead><tr style="background-color: #4472C4"><th align="left" valign="middle"><styled-content style="color: #FFFFFF">Total N=43</styled-content></th><th align="left" valign="middle"><styled-content style="color: #FFFFFF">Stable N=30(%/IQR)</styled-content></th><th align="left" valign="middle"><styled-content style="color: #FFFFFF">eCLAD N=13(%/IQR)</styled-content></th><th align="left" valign="middle"><styled-content style="color: #FFFFFF">P Value</styled-content></th></tr></thead><tbody><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Donor Age</bold></td><td align="left" valign="middle">49.5 (38-57.5)</td><td align="left" valign="middle">49 (39.5-62)</td><td align="left" valign="middle">0.81</td></tr><tr><td align="left" valign="middle"><bold>Donor smoking history</bold></td><td align="left" valign="middle">4 (13.3%)</td><td align="left" valign="middle">1 (7.7%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Female Sex</bold></td><td align="left" valign="middle">18(60%)</td><td align="left" valign="middle">10 (77%)</td><td align="left" valign="middle">0.49</td></tr><tr><td align="left" valign="middle"><bold>Age (years)</bold></td><td align="left" valign="middle">56.2(42.8-62.5)</td><td align="left" valign="middle">59.8(53.2-65.5)</td><td align="left" valign="middle">0.12</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>BMI</bold></td><td align="left" valign="middle">22.6(21.2-28.5)</td><td align="left" valign="middle">23.3(19.7-27.5)</td><td align="left" valign="middle">0.97</td></tr><tr><td align="left" valign="middle"><bold>Smoking History</bold></td><td align="left" valign="middle">21 (70%)</td><td align="left" valign="middle">10 (76%)</td><td align="left" valign="middle">0.72</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Double-Lung Tx</bold></td><td align="left" valign="middle">24 (80%)</td><td align="left" valign="middle">6 (46%)</td><td align="left" valign="middle">0.04<xref ref-type="table-fn" rid="TFN1">*</xref></td></tr><tr><td align="left" valign="middle"><bold>Diabetes</bold></td><td align="left" valign="middle">0 (0%)</td><td align="left" valign="middle">2 (15.4%)</td><td align="left" valign="middle">0.09</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Hypertension</bold></td><td align="left" valign="middle">6 (20%)</td><td align="left" valign="middle">3 (23%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr><td align="left" valign="middle"><bold>Hyperlipemia</bold></td><td align="left" valign="middle">2(6.7%)</td><td align="left" valign="middle">2 (15.4%)</td><td align="left" valign="middle">0.57</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Transplant diagnose</bold></td><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr><tr><td align="left" valign="middle">         <bold>COPD</bold></td><td align="left" valign="middle">9 (43%)</td><td align="left" valign="middle">7 (56.3%)</td><td align="left" valign="middle">0.72</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle">         <bold>α-1 ATD</bold></td><td align="left" valign="middle">4 (13.3%)</td><td align="left" valign="middle">1 (7.7%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr><td align="left" valign="middle">         <bold>Fibrosis</bold></td><td align="left" valign="middle">11 (36%)</td><td align="left" valign="middle">5 (39%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle">         <bold>Other</bold><xref ref-type="table-fn" rid="TFN2">**</xref></td><td align="left" valign="middle">6 (20%)</td><td align="left" valign="middle">0</td><td align="left" valign="middle">0.15</td></tr><tr><td align="left" valign="middle"><bold>CMV mismatch</bold></td><td align="left" valign="middle">6 (20%)</td><td align="left" valign="middle">2 (15%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Tacrolimus CNI</bold></td><td align="left" valign="middle">1 (3%)</td><td align="left" valign="middle">0</td><td align="left" valign="middle">&gt;0.99</td></tr><tr><td align="left" valign="middle"><bold>PGD 2-3</bold></td><td align="left" valign="middle">3 (10%)</td><td align="left" valign="middle">1 (7.7%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Time in ICU (days)</bold></td><td align="left" valign="middle">2 (1-12)</td><td align="left" valign="middle">2 (1-24)</td><td align="left" valign="middle">0.8</td></tr><tr><td align="left" valign="middle"><bold>Baseline FEV1% predicted</bold></td><td align="left" valign="middle">83.1(64.7-101.8)</td><td align="left" valign="middle">64.7 (58.9-83.7)</td><td align="left" valign="middle">0.066</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P31">Statistically significant (p&gt;0.05)</p></fn><fn id="TFN2"><label>**</label><p id="P32">Includes Pulmonary artery hypertension, Scleroderma, Cystic fibrosis, Microlithiasis α-1 ATD: alfa-1 antitrypsin deficiency, eCLAD: early Chronic lung allograft dysfunction, Tx: Transplant, COPD: Chronic obstructive pulmonary disease, CMV: Cytomegalovirus, CNI: Calcineurin inhibitor, PGD 2-3:Primary graft dysfunction grade 2-3, ICU: Intensive care unit, FEV1% predicted: % of Forced expiratory volume during the first second achieved compared to what would be predicted according to the global lung initiative</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>Clinical events between 1- and 12-months post-transplant</title></caption><table frame="box" rules="all"><thead><tr style="background-color: #4472C4"><th align="left" valign="middle"><styled-content style="color: #FFFFFF">Total N=43</styled-content></th><th align="left" valign="middle"><styled-content style="color: #FFFFFF">Stable N=30 (%)</styled-content></th><th align="left" valign="middle"><styled-content style="color: #FFFFFF">eCLAD N=13 (%)</styled-content></th><th align="left" valign="middle"><styled-content style="color: #FFFFFF">P Value</styled-content></th></tr></thead><tbody><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Any Rejection A2 or higher</bold></td><td align="left" valign="middle">1 (3.3%)</td><td align="left" valign="middle">1 (7.7%)</td><td align="left" valign="middle">0.09</td></tr><tr><td align="left" valign="middle"><bold>Anastomotic complications</bold></td><td align="left" valign="middle">1 (3.3%)</td><td align="left" valign="middle">0 (0%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Any infection within 3M</bold></td><td align="left" valign="middle">14 (43.7%)</td><td align="left" valign="middle">10 (76.9%)</td><td align="left" valign="middle">0.055</td></tr><tr><td align="left" valign="middle"><bold>Any viral infection within 3M</bold></td><td align="left" valign="middle">8 (26.7%)</td><td align="left" valign="middle">6 (26.7%)</td><td align="left" valign="middle">0.29</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Any bacterial infection within 3M</bold></td><td align="left" valign="middle">5 (16.7%)</td><td align="left" valign="middle">6 (46.2%)</td><td align="left" valign="middle">0.06</td></tr><tr><td align="left" valign="middle"><bold>Any fungal infection within 3M</bold></td><td align="left" valign="middle">1 (3.3%)</td><td align="left" valign="middle">1 (7.7%)</td><td align="left" valign="middle">0.52</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Any infection</bold></td><td align="left" valign="middle">18 (60%)</td><td align="left" valign="middle">10 (90.9%)</td><td align="left" valign="middle">0.13</td></tr><tr><td align="left" valign="middle"><bold>Any Viral Infection</bold></td><td align="left" valign="middle">10 (33.3%)</td><td align="left" valign="middle">9 (69.2%)</td><td align="left" valign="middle"><bold>0.046</bold><xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Any Fungal infection</bold></td><td align="left" valign="middle">1 (3.3%)</td><td align="left" valign="middle">4 (30.8%)</td><td align="left" valign="middle"><bold>0.024</bold><xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" valign="middle"><bold>Any Bacterial infection</bold></td><td align="left" valign="middle">9 (30%)</td><td align="left" valign="middle">9 (69.2%)</td><td align="left" valign="middle"><bold>0.023</bold><xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>&gt;1 Viral Infections</bold></td><td align="left" valign="middle">2 (6.7%)</td><td align="left" valign="middle">5 (38.5%)</td><td align="left" valign="middle"><bold>0.019</bold><xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" valign="middle"><bold>&gt;1 Fungal infections</bold></td><td align="left" valign="middle">0 (0%)</td><td align="left" valign="middle">1 (7.7%)</td><td align="left" valign="middle">0.30</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>&gt;1 Bacterial infections</bold></td><td align="left" valign="middle">2 (6.7%)</td><td align="left" valign="middle">5 (38.5%)</td><td align="left" valign="middle"><bold>0.019</bold><xref ref-type="table-fn" rid="TFN3">*</xref></td></tr><tr><td align="left" valign="middle"><bold>Samples out of CNI range High</bold></td><td align="left" valign="middle">12 (40%)</td><td align="left" valign="middle">4 (36.4%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr style="background-color: #D9E2F3"><td align="left" valign="middle"><bold>Samples out of CNI range Low</bold></td><td align="left" valign="middle">12 (40%)</td><td align="left" valign="middle">4 (36.4%)</td><td align="left" valign="middle">&gt;0.99</td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle"/></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p id="P33">Statistically significant</p></fn><fn id="TFN4"><p id="P34">A2: rejection grading according to the International Society of Heart and Lung Consensus, grade 2. M: Months, CNI: Calcineurin inhibitor</p></fn></table-wrap-foot></table-wrap></floats-group></article>